◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

ホーム全銘柄 › GMED · English version

Globus Medical (GMED)

公式財務諸表に基づく売上高、利益、キャッシュフローの推移。

HEALTHCARE · ウォール街(米国) · 最終更新: 2026-08-16

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.

主要指標

インタラクティブチャートと全財務諸表を見る → バリュエーションモデル(DCF)→

年次損益計算書

損益計算書TTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-31
売上高合計$3.1B$2.9B$2.5B$1.6B$1.0B$958M$789M$785M$713M$636M$564M$545M$474M$434M$386M$331M$288M$254M
売上総利益$2.2B$2.0B$1.5B$1.0B$759M$719M$572M$605M$554M$486M$429M$412M$364M$334M$311M$263M$234M$213M
売上総利益率 %68.5%67.4%58.9%65.0%74.2%75.0%72.4%77.1%77.6%76.3%76.1%75.7%76.6%76.9%80.5%79.2%81.3%83.6%
営業利益(EBIT)$667M$480M$166M$133M$228M$172M$111M$172M$169M$162M$154M$172M$138M$102M$115M$97M$88M$82M
営業利益率 %21.2%16.3%6.6%8.5%22.3%17.9%14.1%21.9%23.8%25.4%27.3%31.6%29.2%23.4%29.7%29.4%30.4%32.2%
当期純利益$536M$538M$103M$123M$190M$149M$102M$155M$156M$107M$104M$113M$92M$69M$74M$61M$54M$49M
純利益率 %17.0%18.3%4.1%7.8%18.6%15.6%13.0%19.8%21.9%16.9%18.5%20.7%19.5%15.8%19.1%18.3%18.9%19.2%
EBITDA$730M$474M$347M$305M$265M$178M$229M$219M$205M$193M$196M$160M$121M$133M$116M$106M$97M
1株当たり利益(EPS)$3.90$3.92$0.75$1.07$1.85$1.44$1.01$1.52$1.54$1.10$1.08$1.17$0.97$0.73$0.80$0.81$0.72$0.54
発行済株式数(百万株)137M138M115M103M104M101M102M101M98M96M96M95M94M92M75M75M91M

出典: 企業の公開資料(SEC)。数値をご利用の前に SEC EDGAR でご確認ください。

貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は GMED のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/GMED

類似企業

本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。

English version →全銘柄

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.